<DOC>
	<DOCNO>NCT02072447</DOCNO>
	<brief_summary>This study aim determine absolute bioavailability YH4808 use simultaneous oral therapeutic- [ 14C ] -labeled intravenous microdoses .</brief_summary>
	<brief_title>Absolute Bioavailability YH4808 With Accelerator Mass Spectrometry ( AMS ) -Based Microdose Study</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>healthy male subject age 20 45 screening subject weight 55 kg BMI range 20.0 25.0 subject decide participate voluntarily write informed consent form subject clinically significant disease cardiovascular , respiratory , renal , endocrinological , hematological , gastrointestinal , neurological ( central nervous system ) , psychiatric disorder malignant tumor clinically significant allergic disease ( except mild allergic rhinitis ) subject determine eligible screen test ( medical history , physical examination , 12lead ECG , laboratory test , etc ) within 28 day study start subject consider unsuitable inclusion investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>absolute bioavailability ,</keyword>
	<keyword>microdose ,</keyword>
	<keyword>AMS</keyword>
</DOC>